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Abstract
Introduction/Aim. Glycosaminoglycans (GAG) are one of
the main constituents of the connective tissue and cellular
membrane. Their presence has been evidenced in mucosa
and muscular tissue of the urinary bladder of both healthy
individuals and those affected by carcinoma. This suggest
their potential role in the onset of bladder carcinoma and
follow-up of those patients. The aim of the study was to
determine GAG levels in tumor tissue and the surrounding
bladder mucosa in patients with bladder tumor, as well as in
the bladder mucosa in patients with bladder carcinoma, and
to compare the results according to the grade and stage of
tumor and relapse. Methods. Tissue samples were taken in
61 patients (48 males and 13 females), mean age 61.5 years,
range 40–92 years, obtained by transurethral resection
(TUR) of bladder tumor, and 8 healthy persons. Determi-
nation of a total GAG content in the tissue samples was
done by the Whiteman's method and then compared re-
garding the tumor grade and stage. Results. Tumor grade
and stage directly correlated with the levels of GAG. The
GAG levels were significantly higher in tumor samples as
compared to healthy mucosa. Conclusion.  Higher GAG
levels were recorded in all the patients with bladder tumors
comparing to smples obtained from healthy individuals.
GAG levels do not predict tumor relapse.
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Apstrakt
Uvod/Cilj. Glikozaminoglikani (GAG) su glavni sastojci os-
novne supstance vezivnog tkiva i ćelijske membrane. Njihovo
prisustvo dokazano je u mukozi i mišićnom tkivu mokraćne
bešike kako zdravih, tako i obolelih od karcinoma mokraćne
bešike. Ta činjenica ukazuje na potencijalnu ulogu GAG u po-
javi i praćenju obolelih od karcinoma mokraćne bešike. Cilj
ovog rada bio je da se ispita značaj određivanja GAG u tkivu
tumora i mukozi oko tumora mokraćne bešike prema stadiju-
mu i gradusu tumora za predviđanje pojave recidiva superfici-
jelnog tumora mokraćne bešike. Metode. Uzorci tkiva uzeti su
od 61 bolesnika (48 muškaraca i 13 žena) prosečne starosti 61,5
godina, opseg 40–92 godine, tokom transuretralne resekcije
(TUR) tumora mokraćne bešike. Određivanje ukupnog sadr-
žaja GAG u uzorcima tkiva učinjeno je primenom metode
Whiteman, a dobijene vrednosti potom su upoređene prema
gradusu i stadijumu tumora. Rezultati. Dobijene vrednosti
odnosa GAG pokazale su rast shodno rastu gradusa i stadijuma
tumora i taj rast bio je značajan u odnosu na vrednosti GAG u
mukozi zdravih osoba. Nije dobijena značajna razlika u vred-
nosti GAG kod osoba sa recidivom tumora u odnosu na sve
ispitanike, kao grupu u celosti. Zaključak. Kod ispitanika u
svim stadijumima i gradusima tumora dobijene su povišene
vrednosti GAG u odnosu na vrednosti GAG kod ispitanika sa
normalnom mukozom mokraćne bešike, ali se dobijeni rezul-
tati ne mogu koristiti za predviđanje pojave recidiva bolesti.
Ključne reči:
mokraćna bešika, neoplazme; recidiv;
glikozaminoglikani; osetljivost i specifičnost.
Introduction
Urinary bladder carcinoma is quite often asymptomatic
and at the moment of detection invasive carcinoma is already
present in 25% of cases. Out of the remaining 75% of super-
ficial forms in about 15% of cases progression into invasive
carcinoma occurs.
The risk of tumor progression and relapse is paralelly
increased with higher clinical stage and grade as well as the
size and number of primary tumors. In our country, ac-
cording to the latest statistical report for the year 2004 
1 the
incidence of bladder carcinoma was 6.7% for male (the
fourth most common malignancy) and 2.1% for female
population (the ninth most common malignancy), while theStrana 148 VOJNOSANITETSKI PREGLED Volumen 69, Broj 2
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mortality rate was 4% and 1.6% for male and female
population, respectivly.
The change in glucosaminoglycons (GAG) level is in-
teresting in the diagnosis and follow-up of bladder carci-
noma. It has been established that GAG is the main constitu-
ent of the basic layer of the connective tissue and cellular
membrane. Their presence has been evidenced in mucosa
and muscular tissue of the urinary bladder 
2–4 in both healthy
bladders and those affected by carcinoma. Their role in anti-
bacterial adherence and formation of urinary stones 
5–8 is al-
ready known. All this is suggestive for the potential role that
GAG can play in the occurrence of urinary bladder tumors.
Changes occurring in the epithelium and deeper structures
cases of bladder tumors, suggest that the whole bladder mu-
cosa is preparing for the occurrence of malignancy (primary
and recurrent tumor).
The aim of our study was to determine GAG levels in
tumor tissue and bladder mucosa of patients with tumor, as
well as in healthy mucosa of the bladder, and to compare the
results regarding tumor grade and stage as well as in cases of
tumor relapse.
Methods
Our study comprised 61 patients with bladder tumor (48
males and 13 females) aged 40–92 years (average age 61.5
years) and 8 controls with healthy bladder mucosa of the
comparable age (6 males and 2 females).
The material was sampled by transurethral resection
(TUR) in all subjects. Sixty-one tumor biopsies were taken
as well as 46 samples of bladder mucosa adjacent to the tu-
mor and no macroscopic signs of abnormalities. Control
samples were taken by TUR in 8 patients with no signs of
malignancy, but the presence of urinary stones or infections.
The samples were subjected for biochemical analysis as
well as for histological analysis. Hematoxylin eosin was used
for histological staining. The material taken for biochemical
studies was stored at -20°C, and subsequently homogenized at
a Potter-Elvehiem's homogenizer at 3000 rpm. The material
prepared in this way, both tumorous and mucosal tissues, were
studied using the Whitman's method for determination of
GAG. The values of GAG were presented in grams of tissue
proteins, since proteins are a constant parameter in the tissue.
Tissue GAG levels were determined by the Whitman's
method 
9, from a complex with Alcian Blue 8 GX stain (Al-
cian Blue 8 GX 0.5 g/L in 0.05 mol/L Na-acetate buffer with
addition of 0.05 mol/L MgCl2, pH 5.8), subsequently dis-
solved in Na-lauril sulfate. The intensity of color was meas-
ured by a spectrophotometer at 620 nm.
Tissue proteins were determined with Commasi Bril-
liant Blue (CBB) stain by spectrophotometry at 595 nm.
The results were processed by nonparametric statistic
tests: Mann-Whitney U-test, Kruskall-Wallis test and Wil-
coxon test.
Results
Distribution of the patients regarding tumor grade and
gender is given is Table 1.
Two patients with grade III tumors entered the study.
No signs of invasion were found and they were not particu-
larly analyzed in relation to tumor grade.
According to histopathologic findings and clinical pic-
ture, using TNM (Tumor Nodus Metastasis) and World
Health Organization (WHO) clasification systems, tumors
were classified into three stages (Figure 1).
TUMOR STAGE
  Ta
21%
T2
21%
T1
58%
Fig. 1 – Distribution of patients according to the tumor stage
The biochemical evaluation was done in 57 out of 61
tumor samples (in 4 cases due to techical reasons evaluation
was not possible), 46 samples of heatlhy appearing mucosa
from urinary bladder with tumor, and 8 samples of healthy
bladder mucosa (Table 2).
The values of GAG were expressed in mg GAG/g tissue
proteins, in relation to tumor grade in tumor tissue as well as
bladder mucosa of patients with tumor (Table 3).
In Table 4 the relationship between GAG values and
clinical stages of the tumor is given.
According to individual values of GAG in tumor and
mucosal tissue of patients with tumor relapse, no differences
in GAG values were noted which might suggest the occur-
rence of relapse although the values remained within the
range obtained elsewhere.
Two year follow-up of tumor relapses according the
tumor grade and stage is shown in Table 5.
Table 1
Distribution of patients according to gender and tumor grade
Gender Total Grade male female n %
Papilloma 1 1 2 3.3
Grade I 13 3 16 26.2
Grade II 33 8 41 67.2
Grade III 1 1 2 3.3Volumen 69, Broj 2 VOJNOSANITETSKI PREGLED Strana 149
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Table 2
Distribution of glycosaminoglucans (GAG) in different tissue samples
GAG (mg/g tissue proteins) Samples Number of specimens mean (min–max)
Bladder tumor 57 105.52 (19.1–1024.59)
Bladder mucosa 46 142.94 (4.6–1000.0)
Control bladder 8 39.23(18.87–88.0)
Table 3
Glycosaminoglucans (GAG) values in tissue samples of bladder tumor and mucosa
according to the tumor grade
GAG (mg/g tissue proteins) Samples / tumor grade Number of specimens mean (min–max)
Tumor samples
Papilloma 2 37.11 (35.65–38.57)
Grade I 16 75.55 (19.1–137.91)
Grade II 37 120 (24.47–1024.59)
Grade III 2 138.92 (130.84–146.99)
Bladder samples
Papilloma 2 13.54 (10.69–16.39)
Grade I 13 176.5 (18.7–608.7)
Grade II 31 137.21 (4.6–1000.0)
Grade III 0 0
Control bladder samples 8 39.23 (18.87–88.0)
Table 4
Glycosaminoglucans (GAG) values in tissue samples of bladder tumor and mucosa
according to the tumor stage
GAG (mg/g tissue proteins) Samples / tumor stage Number of specifiens mean (min–max)
Tumor samples
Ta 13 52.86 (19.1–114.79)
T1 33 135.37 (24.47–1024.59)
T2 11 78.2 (30.16–146.99)
Bladder samples
Ta 12 98.19 (10.69–25.0)
T1 24 177.29 (16.14–1000.0)
T2 10 114.18 (4.6–250.0)
Control bladder samples 8 39.23 (18.87–88.0)
Table 5
Distribution of relapses according to the tumor grade and stage
 Tumor grade Relapses Tumor stage P I II III n
Ta 1 – – – 1
T1 – 1 6 – 7
T2 – – 4 1 5
P – Papilloma
Discussion
According to the available information on the behavior
of superficial bladder carcinoma, it is diffucult to predict
further course and occurrence of relapses and outcome of the
disease. Not a single tumor marker has been found to have
specificity and sensitivity which would make it useful for
clinical practice. Therefore, efforts have been focused on
detecting a substrate which would satisfy all relevant criteria
for a good tumor marker. In addition to the above, we be-
lieve that the whole bladder mucosa is influenced by car-
cinogens, and that one or more mucosal fields are the vulner-
able sites where the absence of protective factors permit
neoplasm proliferation. It is difficult to say whether the re-
moved primary, solitary neoplastic lesion still presents a lo-
cal predisposing factor for the relapse on the same site, or,
some other sites, relieved from the protective noxa become
new sites of de novo tumor growth since the whole mucosa
suffers the influence of the noxious factor.
A decision to evaluate GAG has been made since the
available referential data suggested their insufficiently stud-
ied role in bladder tumors 
10, 11. We focused on qualitativeStrana 150 VOJNOSANITETSKI PREGLED Volumen 69, Broj 2
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study of GAG intending to identify and possibly, show a cor-
relation of GAG in tumor and mucosa of patients with super-
ficial bladder tumors which might suggest tumor recurrence.
The results of de Klerk 
2 point out that total GAG levels are
mildly reduced in 13 (100%) cases of bladder transitional
cell carcinoma with large individual variations. He believes
that, due to the variability, total GAG level cannot indicate
different grades and stages of tumors. However, our results
indicate the opposite: elevation of total GAG values corre-
lates with the increase in tumor stage and grade. All tumors
had more elevated GAG values in comparison with healthy
mucosa. Moreover, the noted variability in GAG values, in
each individual case, remains within the grade and stage of
the tumor. The content of particular GAG fractions within
the total GAG content cannot be compared since we did not
include a qualitative analysis in our study.
The results of our study concerning total GAG content,
suggest increased GAG levels in tumorous and mucosal tis-
sue in patients with tumors, as compared with the controls.
The difference was statistically significant (p < 0.05). It re-
mains to be answered whether the recorded GAG values re-
sult from the discharge of GAG from tumorous tissue, ie
preparation of the mucosa for the occurrence of tumor, since
the control mucosal tissue does not contain high GAG levels.
We recorded elevation of GAG values with higher tumor
grade. The lowest values are found in papilloma while the
highest were found in cases with tumor grade III. This ap-
plies to GAG values in tumorous tissue, while in the same
group of patients GAG values in mucosa not affected with
tumor is somewhat different. Thus, papillomatous mucosa is
characterized with GAG levels below normal, which may re-
sult from mucosal stress. Tumor increase GAG levels in-
crease in the surrounding tissue with increase of tumor grade,
but not strictly following the tumor grade. It is, nevertheless
always increased, and the difference from the controls is sta-
tistically significant (p  <  0.05). Clinically, GAG levels in
tumor tissue rises with the incerase in tumor stage. The low-
est increase was noted in Ta stage and it is no statistically
significant (p  >  0.05) when compared with the controls,
while in stages T1 and T2 showed a significant increase.
Mucosa of patients with tumor also shows increased
GAG levels in all stages of the disease, and the difference
from the controls was statistically significant (p < 0.05).
Out of the 61 patients, relapse was noted in 13 in a 24-
month period.
Relapse most commonly occurred in patients with grade
II tumor, as well as in those with T1 and T2 stages. In none
of the analyzed cases with relapse, GAG values in tumor tis-
sue and mucosa deviated from other analyzed cases of the
group as a whole, so that the obtained results cannot be used
to predict relapse of the disease.
Conclusion
Our study shows that GAG levels rise with the rise in
tumor grade and stage in the tumor tissue as well as in sur-
rounding mucosa. Elevation of GAG levels in mucosa of pa-
tients with tumor was higher than in tumor itself, suggesting
a very important question to be answered.
Whether tumor is an only manifestation of a process
occurring in the bladder mucosa with future behavior what is
probably already determined remains unclear.
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